Endo higher after FDA proposes restrictions on compounded medications

The FDA today proposed restricting the ability of companies that produce compounded medications in bulk from using three substances that are active ingredients in approved drugs, Reuters reports. The three substances include vasopressin, the active ingredient in Endo International’s (ENDP) blood pressure drug Vasostrict, which has been the subject of a lawsuit targeting how the FDA regulates drug compounding, Reuters adds. Shares of Endo are up 6%, or $1.00, to $16.54 in midday trading.

https://bit.ly/2wizl8r

Edit